{
    "name": "Rho(D) immune globulin",
    "comment": "Rx",
    "other_names": [
        "RhoGAM",
        "Gamulin Rh",
        "HypRho D",
        "MicRhoGAM",
        "Rhesonativ",
        "HyperRHO",
        "Rhophylac",
        "WinRho SDF"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/rhogam-hyperrho-s-d-rho-d-immune-globulin-343143",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known if excreted in breast milk, no adverse effects reported"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known if excreted in breast milk, no adverse effects reported"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Intravascular Hemolysis (IVH) with WinRho SDF",
                    "description": [
                        "Intravascular hemolysis (IVH) leading to death has been reported in patients treated for ITP with WinRho SDF",
                        "IVH can lead to clinically compromising anemia and multisystem organ failure including acute respiratory distress syndrome (ARDS)",
                        "Serious complications, including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported",
                        "Monitor closely in health care setting for at least 8 hr after administration",
                        "Perform dipstick urinalysis at baseline, 2 hr, and 4 hr after administration and prior to end of the monitoring period",
                        "Alert patients to signs and symptoms of IVH, including back pain, shaking chills, fever, and discolored urine or hematuria",
                        "Absence signs and/or symptoms of IVH within 8 hr do not indicate IVH cannot occur subsequently",
                        "Post-treatment laboratory tests should be performed if IVH suspected and include plasma hemoglobin, urinalysis, haptoglobin, LDH, and plasma bilirubin (direct and indirect)"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "NEVER GIVE TO NEONATE",
                "Do not administer IM for ITP",
                "WinRho SDF: risk of rare but potentially fatal intravascular hemolysis in ITP pts",
                "Maltose-containing IVIG products (eg WinRho SDF) may give false highs in certain glucose-testing systems",
                "Avoid live vaccines for 3 mth",
                "IgA deficiency",
                "Avoid gluteal IM if possible, if not inject only in upper outer quadrant"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "Rho(D) immune globulin, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "Rho(D) immune globulin, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "Rho(D) immune globulin, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "Rho(D) immune globulin, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "Rho(D) immune globulin, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "Rho(D) immune globulin, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of Rho(D) immune globulin by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of Rho(D) immune globulin by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of rubella vaccine by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "Rho(D) immune globulin decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Minor/Significance Unknown. Separate by 3 months."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Tenderness",
            "percent": null
        },
        {
            "name": "Allergic reaction",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Rare elevation in total bilirubin secondary to rapid RBC destruction when given following transfusion mismatch",
            "percent": null
        }
    ]
}